3 Reasons Eli Lilly Remains a Buy

Eli Lilly (NYSE: LLY) became the first $1 trillion pharmaceutical company late last year, built on the strength of its GLP-1 empire used for diabetes and weight loss. Pharmaceutical stocks have struggled in 2026, but Eli Lilly's shares are up more than 45% over the past year. And over the past three months, its pedestrian 2% rise has outpaced its competitors.The Indianapolis-based healthcare company has several catalysts that should continue to drive its share growth, led by its expanded GLP-1 earnings, its willingness to invest its cash to improve its pipeline through acquisitions, and the continued rise of its high-margin specialty drugs. Here's more on all three.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool